PhaseBio Says Antiplatelet Candidate Achieved Primary Reversal Endpoint In Late-Stage Study

PhaseBio Pharmaceuticals Inc PHAS has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of ticagrelor.
The trial included patients with urgent surgery or an invasive procedure or experiencing uncontrolled major or life-threatening bleeding.
Bentracimab was shown to reverse the effects of AstraZeneca Plc's AZN blood thinner Brilinta (ticagrelor) in an interim analysis of more than 100 patients.
Patients who took bentracimab saw a 135% reduction in platelet inhibition within 5 to 10 minutes of infusion and saw those effects last over 24 hours.
Bentracimab appeared safe. Though 91% of patients reported a treatment-emergent side effect, the most common was pain associated with the surgical procedure.
Eight experienced thrombotic events, though none of the cases were tied to bentracimab.
Bentracimab is a monoclonal antibody fragment that binds to Brilinta when it's in that off state and removes it from the platelet environment.
PhaseBio is still recruiting patients with uncontrolled major or life-threatening bleeding for the REVERSE-IT trial and aims to be fully enrolled as soon as possible.
Related Link: PhaseBio's Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study
Price Action: PHAS shares are down 20.30% at $2.96 during the market session on the last check Monday.
Editor's Note: The post has been revised with an updated headline to exclude side effects being treatment related.

Overview Rating:

Speculative

0100